![]() Adverum Biotechnologies Adverum Biotechnologies (formerly known as Avalanche Biotechnologies) is a clinical-stage gene therapy company targeting unmet medical need in ophthalmology and rare diseases. | ![]() Neurotech Neurotech Pharmaceuticals is a biotechnology company focused on the development of therapies for chronic eye diseases. | ||||
Founding Date | Founding Date 2014 | Founding Date 2006 | Founding Date 2018 | Founding Date 1995 | Founding Date 2016 |
Type | Type Private | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | Tags Healthcare | ||||
Locations | Locations South San Francisco, US HQ South San Francisco, US | Locations Redwood City, US HQ Philadelphia, US | Locations South San Francisco, US HQ Redwood City, US South San Francisco, US | Locations Cumberland, US HQ | Locations Cambridge, US HQ |
Employees | Employees 1914% decrease | Employees 11419% increase | Employees 121 | Employees 1203% increase | Employees 85 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 161.4 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 159.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $19.9m (FY, 2024) |
Net income | Net income N/A | Net income ($130.9m) (FY, 2024) | Net income ($131.1m) (FY, 2025) | Net income N/A | Net income ($131.7m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 34m | Total funding raised $ 70.7m | Total funding raised $ 191m | Total funding raised $ 49.1m | Total funding raised $ 235m |

Adverum Biotechnologies (formerly known as Avalanche Biotechnologies) is a clinical-stage gene therapy company targeting unmet medical need in ophthalmology and rare diseases.
View company
Maze Therapeutics is a clinical-stage biopharmaceutical company.
View company
Neurotech Pharmaceuticals is a biotechnology company focused on the development of therapies for chronic eye diseases.
View company
Generation Bio is a genetic medicines company creating gene therapy.
View company